BIOMAT Database Logo BIOMAT Database Logo

Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma. 2016

Katelyn Hood, and Arpita Shah
Nationwide Children's Hospital, Columbus, Ohio, and Georgia Regents Medical Center, The University of Georgia College of Pharmacy, Augusta, Georgia.

UI MeSH Term Description Entries

Related Publications

Katelyn Hood, and Arpita Shah
Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
January 2015, Future oncology (London, England),
Katelyn Hood, and Arpita Shah
Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
March 2017, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners,
Katelyn Hood, and Arpita Shah
Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
January 2014, OncoTargets and therapy,
Katelyn Hood, and Arpita Shah
Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review.
August 2015, Therapeutic advances in hematology,
Katelyn Hood, and Arpita Shah
FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma.
June 2015, Clinical cancer research : an official journal of the American Association for Cancer Research,
Katelyn Hood, and Arpita Shah
A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.
March 2015, British journal of haematology,
Katelyn Hood, and Arpita Shah
Characterizing the belinostat response in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma.
August 2020, Leukemia & lymphoma,
Katelyn Hood, and Arpita Shah
Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma.
July 2006, British journal of haematology,
Katelyn Hood, and Arpita Shah
Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
October 2014, Cancer treatment reviews,
Katelyn Hood, and Arpita Shah
Belinostat (Beleodaq) for peripheral T-Cell lymphoma.
April 2015, The Medical letter on drugs and therapeutics,
Copied contents to your clipboard!